secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001628280-22-017489
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex holds 2022 annual meeting; re-elects seven directors, appoints Steven Rubin as Lead Independent Director
--------------------------------------------------------------------------------

- All seven director nominees elected at June 16 annual meeting; votes ranged from ~28.3M to ~37.3M for.
- Shareholders ratified Marcum LLP as auditor for FY2022 with 47.7M for, 1.8M against.
- Advisory say-on-pay proposal passed with 36.0M for, 1.1M against.
- Board appointed Steven Rubin as Lead Independent Director following Kurt Gustafson's departure.
- Board committee assignments reconstituted; Rubin chairs Audit, Patrick chairs Compensation, Cohen chairs Nominating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022017489/0001628280-22-017489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022017489/cdxc-20220616.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-017489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer